English | 简体中文 | 繁體中文 | 한국어
 All Press Releases
 Medicine BioTech
Everest Medicines Announces Acceptance of VELSIPITY New Drug Application in Hong Kong
Dec 02, 2024 10:34 HKT
雲頂新耀宣佈中國香港衛生署正式受理伊曲莫德(VELSIPITY(R))
Dec 02, 2024 10:30 HKT
云顶新耀宣布中国香港卫生署正式受理伊曲莫德(VELSIPITY(R))
Dec 02, 2024 10:25 HKT
Hua Medicine Announces Successful U.S. Phase I Results on Its 2nd Generation GKA Candidate
Nov 30, 2024 21:08 HKT
華領醫藥宣佈成功完成在美國開展的第二代葡萄糖激酶激活劑I期臨床研究
Nov 30, 2024 20:56 HKT
华领医药宣布成功完成在美国开展的第二代葡萄糖激酶激活剂I期临床研究
Nov 30, 2024 20:46 HKT
Hua Medicine Announces Successful H.K. SENSITIZE Study Results at the CBIIC
Nov 30, 2024 20:34 HKT
華領醫藥宣佈成功完成在中國香港開展的SENSITIZE研究
Nov 30, 2024 20:11 HKT
华领医药宣布成功完成在中国香港开展的SENSITIZE研究
Nov 30, 2024 19:58 HKT
NEFECON(R) Included in National Reimbursement Drug List (NRDL)
Nov 29, 2024 10:48 HKT
耐賦康(R)納入新版國家醫保藥品目錄
Nov 29, 2024 10:45 HKT
耐赋康(R)纳入新版国家医保药品目录
Nov 29, 2024 10:42 HKT
「依拉環素臨床應用綜合評價項目」終期報告發佈
Nov 26, 2024 11:11 HKT
'依拉环素临床应用综合评价项目'终期报告发布
Nov 26, 2024 11:04 HKT
Everest Medicines Announces NEFECON(R)'s Full Approval in South Korea
Nov 19, 2024 17:37 HKT
雲頂新耀宣佈耐賦康(R)在韓國獲批 商業化進程再創里程碑
Nov 19, 2024 17:28 HKT
云顶新耀宣布耐赋康(R)在韩国获批 商业化进程再创里程碑
Nov 19, 2024 17:10 HKT
雲頂新耀宣佈耐賦康(R)Ⅲ期試驗開放標籤第二療程擴展研究積極結果
Nov 11, 2024 12:23 HKT
云顶新耀宣布耐赋康(R)Ⅲ期试验开放标签第二疗程扩展研究积极结果
Nov 11, 2024 12:15 HKT
Everest Medicines Announces the Launch of VELSIPITY(R) in the Guangdong-Hong Kong-Macau Greater Bay Area
Oct 25, 2024 11:28 HKT
<< Previous  Next >>
Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: